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Brain size regulations by cbp 
haploinsufficiency evaluated by  
in-vivo MRI based volumetry
Juan C. Ateca-Cabarga1, Alejandro Cosa2, Vicente Pallarés2, José P. López-Atalaya2, 
Ángel Barco2, Santiago Canals2 & David Moratal1
The Rubinstein-Taybi Syndrome (RSTS) is a congenital disease that affects brain development 
causing severe cognitive deficits. In most cases the disease is associated with dominant mutations 
in the gene encoding the CREB binding protein (CBP). In this work, we present the first quantitative 
analysis of brain abnormalities in a mouse model of RSTS using magnetic resonance imaging (MRI) 
and two novel self-developed automated algorithms for image volumetric analysis. Our results 
quantitatively confirm key syndromic features observed in RSTS patients, such as reductions in brain 
size (−16.31%, p < 0.05), white matter volume (−16.00%, p < 0.05), and corpus callosum (−12.40%, 
p < 0.05). Furthermore, they provide new insight into the developmental origin of the disease. By 
comparing brain tissues in a region by region basis between cbp+/− and cbp+/+ littermates, we found 
that cbp haploinsufficiency is specifically associated with significant reductions in prosencephalic 
tissue, such us in the olfactory bulb and neocortex, whereas regions evolved from the embryonic 
rhombencephalon were spared. Despite the large volume reductions, the proportion between 
gray-, white-matter and cerebrospinal fluid were conserved, suggesting a role of CBP in brain size 
regulation. The commonalities with holoprosencephaly and arhinencephaly conditions suggest the 
inclusion of RSTS in the family of neuronal migration disorders.
The Rubinstein-Taybi syndrome (RSTS, MIM 180849)1 is a congenital, autosomal dominant disorder 
with rare incidence (1:100,000—1:125,000 human newborns)2–4. The clinical picture of the syndrome 
was first described in 19575 and includes mental impairment, growth delay, skeletal abnormalities, hyper-
telorism, and microcephaly6,7. The main cause of RSTS are heterozygous mutations of the CREBBP gene 
(chromosome 16p13.3)8, which occurs in 40–60% of the diagnoses3,9,10. An alternative cause is a mutated 
EP300 gene (22q13.2), which happens in 3% of the RSTS diagnoses11. CREBBP and EP300 encode two 
paralog transcriptional co-activators with intrinsic lysine acetyltransferase (KAT) activity known as 
CREB binding protein (CBP) and p3007, respectively. Both proteins are highly similar and thought to 
play a major role in transcriptional regulation. Research in mouse models of RSTS, such as the Crebbp 
haploinsufficient mouse (cbp+/−)12 has revealed that these animals present similar features to patients, 
specifically cognitive impairment, growth delay and anatomical abnormalities. Additionally, it has been 
recently shown that CBP also plays a critical role in the regulation of adult neurogenesis13 and the dif-
ferentiation of the cortical neural progenitor cells14.
A considerable number of studies and case reports have included brain imaging exams in RSTS 
patients15–38. These studies have consistently shown that microcephalia is a main feature in RSTS, as 
confirmed by a meta-analysis of 732 patients39. Other abnormalities, such as white matter abnormali-
ties25,26,31, corpus callosum dysgenesis17,24,26,33,35 and abnormalities20,27, and cortical dysmorphologies31,35 
including pachygiria21 and malgyration35 have been also reported. All these features may be correlated 
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with the characteristic cognitive impairment. Preliminary brain images studies in mouse models of RSTS 
have also revealed some gross abnormalities in brain size13,40.
Most of these studies, both in mice and humans, were qualitative, and a precise description of the 
impact of CBP deficiency in brain development and structure is still lacking. To address this situation, 
we performed a quantitative volumetric study of brain structure in the RSTS mouse model of Crebbp 
haploinsufficient. Whereas traditional volumetry, also known as stereology, calculates these volumes 
based on histologic sections of the ex vivo brain, neurocomputational volumetry techniques allow the 
automatic analysis of brain images acquired in vivo by Magnetic Resonance Imaging (MRI) or Computed 
Tomography (CT), avoiding morphometric distortions introduced by histological tissue preparation41 
and therefore providing a more precise quantification of brain anatomy42. We have used two in-house 
developed algorithms for automated volumetry analysis based on MRI images acquired at 7T to unveil 
the selective impact of CBP deficiency in the development of different brain regions. We provide novel 
evidences suggesting that the brain of RSTS mice present holoprosencephaly, composed of important 
dysgenesis in the olfactory bulb and cortex and suggestive of an underlying neuronal migration disorder. 
The latter conclusion is also supported by case reports in RSTS patients reporting cortical abnormalities.
Materials and Methods
Animal preparation. Cbp+/− mice12 (CBP group) and control littermates (WT group) were generated 
as previously described13. Adult mice (95 to 118 days old, WT group: 104,17 ± 7,70 days old, CBP group: 
106,00 ± 7,00 days old) were weighted 14.5 to 28 g (WT group: 24.6 ± 2.7 g, CBP group: 17.8 ± 2.3 g, total: 
21.5 ± 4.3 g). These mice are maintained on a DBA and C57BL/6J mixed background because cbp+/− 
mice are not viable in a pure C57BL/6J background40,43. Mice were maintained according to animal care 
standards established by the European Union and all the protocols were approved by the Institutional 
Animal Care and Use Committee and carried-out in accordance with the approved guidelines.
Image acquisition. Before the image acquisition, the animals were anesthetized with isoflurane. 
During the acquisition, the head of the animal was situated in a stereotactic frame while temperature, 
cardiac frequency and oxygen saturation (SpO2) were monitored. The images were acquired with a 7-T 
MRI scanner (Bruker BioSpin, Ettlingen, Germany) under coronal 3D T1-weighted configuration, using 
an EPI sequence with the following parameters: TR = 360 ms, TE = 10 ms, 35 averages, in plane resolu-
tion 86 × 86 μ m, slice thickness 0.35 mm, with a matrix size of 256 × 256, obtaining 17 DICOM images 
(Fig. 1a).
Common image preprocessing. The common image preprocessing stage consisted in three tasks. 
Firstly, the DICOM images were converted to the NIfTI format. Afterwards, in order to accommodate 
them to the software that implements the two image processing algorithms (further detailed below), the 
images were reoriented by means of the FMRIB Software Library (FSL)44 (Oxford Centre for Functional 
MRI of the Brain, Oxford, United Kingdom) (Fig.  1b). Finally, brain segmentation was performed by 
means of the Brain Extraction Tool (BET)45, which is also included in FSL. This operation basically 
consists in skull-stripping by fitting a deformable model to the brain surface, thus producing the clean 
intracranial volume used for brain tissues and brain regions volumetry (Fig. 1c).
Brain Tissues Volumetry. For the volumetric analysis of the brain tissues, the already extracted brain 
images were segmented in their three constituent tissues, i.e., grey matter (GM), white matter (WM) 
and cerebrospinal fluid (CSF) (Fig. 1d–f). This process was carried out with the Unified Segmentation 
algorithm46, included in the Statistical Parametric Mapping (SPM) software (Wellcome Trust Centre for 
Neuroimaging, London, United Kingdom). This algorithm also spatially normalizes the images with the 
assistance of mouse brain tissue probability maps (TPM)47. Each one of the three resulting images is 
composed by voxels whose intensity indicates the probability of belonging to the correspondent tissue. In 
order to render the voxels that most probably belong to each of the three tissues, the three segments were 
binarized. Lastly, a self-developed algorithm was run to compute the volume of each tissue by summing 
all the belonging voxels and multiplying by the voxel volume. Two-tailed Student’s t-tests were applied in 
order to show significant differences in the volume values between CBP and WT groups.
Brain Regions Volumetry. For the brain regions volumetric analysis, the already extracted brain 
images were segmented in their 43 constituent regions, according to the Kovačević atlas of the mouse 
brain48. This process was carried out by superposing the atlas to each individual brain image, which was 
done by a combination of spatial transformations. Firstly, the atlas was spatially normalized from its 
native space to the space of the TPM and then the atlas in the space of the TPM was spatially normal-
ized in order to adapt to each of the 11 image spaces, each one from one individual (Fig. 1g). Finally, 
in a similar way to the brain tissue volumetry, the volume of each region was computed by summing all 
the belonging voxels and multiplying by the voxel volume prior to two-tailed Student’s t-tests that show 
significant differences among both groups.
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Results
While there have been few in vivo volumetry studies in mouse models of intellectual disability disor-
ders42,49, to the best of our knowledge we have developed and applied the first automated volumetry 
analysis of the mouse brain conducted in vivo.
Brain tissue volumetry. We report the volumes of gray matter (GM), white matter (WM), and cer-
ebrospinal fluid (CSF) from 11 subjects (5 cbp+/− mice and 6 wild type littermates). Results reveal that 
the brains of CBP group are smaller than those of the WT group (Fig.  2). Specifically, GM, WM, and 
CSF volumes are significantly lower in CBP subjects (−16.43% [p < 0.0001], −16.00% [p = 0.005], and 
−34.55% [p = 0.044], respectively). Similarly, brain volume, composed by GM and WM, significantly 
changed by − 16.31% (p < 0.0001) whereas total intracranial volume (TICV), formed by the brain and 
CSF volumes, significantly changed by − 17.20% (p < 0.0001). In contrast to the absolute volume values, 
Figure 1. Block diagram and intermediate results of the methods. The preparation of the 11 animals 
(6 WT, 5 CBP) is followed by the acquisition of magnetic resonance images (Panel (a)). The common image 
preprocessing stage is composed by format conversion, reorientation (Panel (b)), and brain segmentation, 
which produces an extracted brain image (Panel (c)). At this point, the procedure splits into two image 
processing algorithms. Brain tissues volumetry further segments the previously extracted brain into three 
substances (grey matter, white matter, and cerebrospinal fluid, Panels (d–f)) and obtains their volumes for all 
the subjects. On the other hand, brain regions volumetry implies a combination of normalizations to fit the 
atlas to each of the brain images in order to get the regional volumes of the subjects (Panel (g)). Progressive 
overlappings (1–3) of segmented regions over brain axial slices from selected CBP (Panel (g), left column) 
and WT (Panel (g), right column) subjects are shown. All the resulting volumes were compared by means of 
t-tests.
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the proportions between the three tissue classes are kept constant in both groups. Regarding brain tissue 
ratios, the GM- and WM-to-brain-volume ratios along with GM-, WM-, CSF- and brain-to-TICV ratios 
did not significantly change between groups (p > 0.05). In other words, the brains are reduced in volume 
but the ratios are unaltered, which leads us to preliminary conclude that, CBP hemydeficiency provokes 
a down-scaling effect in the brain.
Brain regions volumetry. We report the volumes of 43 brain regions (according to the Kovačević 
atlas of the mouse brain48) for each of the 11 subjects. In 41 of the 43 regions of the CBP group, a vol-
ume reduction was observed (obtaining a volume change of −10.5 ± 4.6% [mean ± standard deviation]), 
being significant (p < 0.05) in 25 of the 41 regions (mean volume change of − 13.34 ± 1.41%).
When the changes in volume per region were mapped on the mouse brain atlas (Fig. 3), we identified 
three zones of different developmental origin showing differential behaviors. First, the posterior part of 
the brain (cerebellum and brain stem), which is derived from the embryonic rhombencephalon, showed 
no significant reduction in volume (− 0.68 ± 0.21%). Second, regions that are developmentally derived 
from the embryonic prosencephalon, such as the telencephalon and diencephalon, showed the largest 
reduction in volume (− 12.51 ± 0.36%). Finally, the anterior part of the brain (olfactory bulb) showed a 
lower but significant volume reduction (− 6.28%). Interestingly, our quantification reveals that cortical 
and corpus callosum volumes are equally reduced (− 12.79% and − 12.40% respectively).
Validation of volumetric results. In order to validate the results from the volumetric analysis of the 
brain tissues and regions using the novel algorithms, we compared our results with those from Kovačević 
et al.48. The volumes reported for the WT group are coincidental with those presented by them. The small 
differences in absolute volume values may result from the fact that Kovačević and colleagues used inbred 
mice whereas we used a mixed C57/DBA background. Besides, Kovačević et al. analyzed images from ex 
vivo mouse brains while this work has dealt with in vivo brain images.
Discussion
Our results show two novel observations. First, consistent with studies in humans, we quantitatively 
confirm the existence of microcephaly and WM abnormalities in the brain of cbp+/− mice. We quan-
titatively confirm a drastic reduction (− 16.31%) in brain volume associated to cbp haploinsufficiency, a 
finding in good agreement with the characteristic microcephaly associated to RSTS39. Our results further 
show that microcephaly is not only produced by GM hypoplasia, since a concomitant and proportional 
decrease (− 16.00%) of WM volume was also found. Previous studies and case reports support this con-
clusion showing WM abnormalities25 and volume reductions26,31 in RSTS patients.
Second, our results suggest for the first time that CBP plays a differential role in the control of the 
development of prosencephalic regions, including the olfactory bulb and neocortex. Interestingly, in 
these areas tissue reductions kept a constant proportion, which suggests a role for CBP in brain size regu-
lation. These results quantitatively confirm key syndromic features of RSTS, such as microcephaly, as well 
as anomalies in the WM, corpus callosum, and cortex. In particular, our results show that the regions 
evolved from the embryonic prosencephalon are greatly reduced in cbp+/− subjects (− 12.51 ± 0.36%). 
This could point to a mild form of holoprosencephaly (HPE, MIM 236100), which has been already 
Figure 2. Results of the brain tissues volumetry analysis. Volumes (mean ± standard deviation) of the 
three brain tissues (Grey Matter, White Matter, and Cerebrospinal Fluid) and their ratios are represented 
for Wildtype (6 subjects) and CBP group (5 subjects). Both groups show similar proportions of the three 
matters, which allows us to conclude that Rubinstein-Taybi Syndrome has no effect in terms of brain tissues 
proportion.
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linked with RSTS57,50. HPE is also associated with Dandy-Walker malformation (OMIM 220219)51, that 
has been also reported in RSTS patients29,34,35,37,52,53, and facial dysmorphism50, found in this RSTS mouse 
model13. The volumetric results in the prosencephalon drive two important observations. On the one 
hand, the volume of the cortex is greatly reduced in cbp+/− animals, pointing to the diagnosis of cortical 
atrophy. On the other hand, the olfactory bulb is also reduced (although less dramatically), what could 
be related to arhinencephaly, a diagnose that describes hypoplasia or absent olfactory tracts and bulb 
and that has been equally linked to HPE and RSTS57,50. Interestingly, HPE and arhinencephaly share an 
underlying etiology: they are both considered neuronal migration disorders (NMD). A perturbed neu-
ronal migration mechanism could be the product of a failure in the neurogenesis or lack of differentiation 
of the progenitor cells to produce the three neural lineages (neurons, astrocytes, and oligodendrocytes). 
In fact, such defects have been recently shown to occur in cbp haploinsufficiency during development14,54. 
Furthermore, CBP deficiency is also associated with a reduction of the number of newborn neurons in 
response to environmental enrichment in adult mice13.
Neuronal migration is a fundamental process in the development of the cortex, which in normal 
conditions is composed by six layers, created in an inside-out manner by means of subsequent waves of 
radially migrating neurons. NMDs are known to cause an abnormally thin cortex55, and cortical defects 
like (micro)lissencephaly, (poli)microgyria and pachigyria, observed in RSTS21. Furthemore, malgyration 
and microscopic abnormalities of the cytoarchytecture of the cerebral cortex35 along with “abnormal 
cortical infoldings”31 have also been reported in RSTS patients. NMD-caused microlissencephaly is also 
shown to contribute to microcephaly55, a feature often found in RSTS patients and reported here for the 
first time in cbp+/− mice.
More research in RSTS needs to be done to clarify the causes of this congenital disorder. Effective 
clinical diagnosis is fundamental for the early detection of RSTS. While there exist RSTS clinical guide-
lines3,4, there is a lack of established diagnostic criteria for the disease21 and the inclusion of neuroimaging 
studies in the clinical workflow has been proposed15,17,18,21–23,25,29,37,56. Our results provide strong evidence 
in support of neuroimaging-assisted diagnosis to reach early detection and treatment of RSTS-associated 
disorders. Furthermore, they offer neurobiological insight into the role of CBP in normal brain devel-
opment, and the consequences of its haploinsufficiency in RSTS models. The advance in the field will 
contribute to a better understanding of the disease and will help its diagnosis.
Figure 3. Results of the brain regions volumetry analysis. Colored maps indicating regional volume 
change (in %) of CBP group mean brain with respect to WT group are shown at axial slices Z = 2 (a), Z = 5 
(b), Z = 9 (c), and Z = 14 (d) of the three-dimensional magnetic-resonance image. Brain regions can be 
grouped in three zones according to their behavior: regions evolved from the embryonic rhombencephalon 
that experiment no significant volume change (− 0.68 ± 0.21%, blue regions), olfactory bulb that shows a 
low level of volume reduction (− 6.28%, green regions), and regions developed from prosencephalon, which 
show a higher reduction (− 12.51 ± 0.36%, orange regions).
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